GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Other Long-Term Liabilities

Sinovac Biotech (Sinovac Biotech) Other Long-Term Liabilities : $0.6 Mil (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Other Long-Term Liabilities?

Sinovac Biotech's other long-term liabilities for the quarter that ended in Jun. 2023 was $0.6 Mil.

Sinovac Biotech's quarterly other long-term liabilities increased from Jun. 2022 ($0.1 Mil) to Dec. 2022 ($0.2 Mil) and increased from Dec. 2022 ($0.2 Mil) to Jun. 2023 ($0.6 Mil).

Sinovac Biotech's annual other long-term liabilities declined from Dec. 2020 ($0.9 Mil) to Dec. 2021 ($0.4 Mil) and declined from Dec. 2021 ($0.4 Mil) to Dec. 2022 ($0.2 Mil).


Sinovac Biotech Other Long-Term Liabilities Historical Data

The historical data trend for Sinovac Biotech's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Other Long-Term Liabilities Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sinovac Biotech Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.


Sinovac Biotech Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022